Chemistry Department, Azarbaijan Shahid Madani University, Tabriz, Iran.
Drugs Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Anticancer Agents Med Chem. 2018 Feb 7;17(14):1898-1914. doi: 10.2174/1871520617666170522124711.
The need for therapeutically effective anticancer drug delivery systems constantly persuades researchers to explore novel strategies.
In this study a novel cubane based antibacterial nanocomposite was tailored as dual chemotherapy drug delivery vesicle in order to increase the therapeutic outcome in cancer therapy.
The physico-chemical characterization of engineered nanocarrier was assessed by Fourier transforms infrared spectroscopy (FTIR), Hydrogen nuclear magnetic resonance spectroscopy (1H NMR), Thermogravimetric analysis (TGA), and Field emission scanning electron microscopy-energy dispersive using X-ray (FESEMEDX). The antibacterial activity of novel developed nanocomposite was tested by determining minimum inhibitory concentration (MIC) values against Pseudomonas aeruginosa, Escherichia Coli and Candida albicans.
In order to investigate the efficacy of novel engineered nanocomposite (with average particle size of 50 nm) as dual anticancer drug delivery, DOX and MTX were bind to nanocarrier with encapsulation efficiency and loading content of around 97.3 ± 2.7% and 20.8 ± 1.6 %, respectively. Dual drugs released simultaneously with distinct tumor targeted, pH responsive sustained release manner. Moreover, the probable antitumoral activity of this engineered nanocomposite system against MCF7 cell lines was evaluated by MTT assay and cell cycle studies. The outcomes showed that novel engineered nanocomposite had no cytotoxic effects, while DOX@MTX-loaded nanocomposite possessed higher growth inhibition property and higher S-phase arrest as compared to cells treated with DOX@MTX alone.
It was concluded that this novel cubane based drug delivery vehicle could process antibacterial and anticancer therapeutics spontaneously, representing promising tumor targeted system in nanomedicine.
治疗有效的抗癌药物输送系统的需求不断促使研究人员探索新的策略。
在这项研究中，一种新型立方烷基抗菌纳米复合材料被设计为双重化疗药物输送囊泡，以提高癌症治疗的治疗效果。
通过傅里叶变换红外光谱（FTIR）、氢核磁共振光谱（1H NMR）、热重分析（TGA）和场发射扫描电子显微镜-能量色散 X 射线（FESEM-EDX）评估了工程纳米载体的物理化学特性。通过测定对铜绿假单胞菌、大肠杆菌和白色念珠菌的最小抑菌浓度（MIC）值来测试新型纳米复合材料的抗菌活性。
为了研究新型工程纳米复合材料（平均粒径为 50nm）作为双重抗癌药物输送的功效，将 DOX 和 MTX 与纳米载体结合，包封效率和载药量约为 97.3±2.7%和 20.8±1.6%。双重药物同时释放，具有明显的肿瘤靶向、pH 响应持续释放的特点。此外，通过 MTT 测定和细胞周期研究评估了该工程纳米复合材料系统对 MCF7 细胞系的可能抗肿瘤活性。结果表明，新型工程纳米复合材料没有细胞毒性，而 DOX@MTX 负载的纳米复合材料比单独用 DOX@MTX 处理的细胞具有更高的生长抑制特性和更高的 S 期阻滞。
综上所述，这种新型立方烷基药物输送载体可以自发地进行抗菌和抗癌治疗，代表了纳米医学中具有前景的肿瘤靶向系统。
